The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 5.97 — safe zoneOK
- Earnings-manipulation signal · Beneish M -3.08 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as BIO-TECHNE Corp reports it. History and quarterly detail are in the app.
- Protein Sciences$870.2M
- Diagnostics And Spatial Biology$346.3M
- All Other Segments$4.2M
Leadership changes
From BIO-TECHNE Corp's own filings, the day they're filed.
- Becton Dickinson · Chief Executive Officer · departureeff. 2024-02-01
- Judith Klimovsky · director · appointment
- Roeland Nusse · Directors · departure
Latest filings
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-06
- 8-K · Company announcement2026-02-11
- 10-Q · Quarterly report2026-02-04
- 8-K · Company announcement2026-02-04
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BIO-TECHNE Corp, every answer cited🔒
- The Intelligence Brief — added when BIO-TECHNE Corp's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.